Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Overview of attention for article published in Lancet Oncology, January 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

news: 7 news outlets
blogs: 1 blog
twitter: 27 X users

patent: 2 patents
guideline: 3 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 109 Mendeley

So far, Altmetric has seen 1 podcast episode.

65 - Prescrivibilità di Erdafitinib per il trattamento dei tumori uroteliali FGFR3 mutati

"We're on the ball" - Nuovi farmaci e nuove indicazioni, 23 Dec 2025

A cura di Eleonora Lai, Castelfranco Veneto Oggi ci focalizziamo sullo sviluppo clinico e regolatorio di erdafitinib nel…

This page shows the most recent posts that mention this research output. Click here to find out how to access more activity.